Topic: companion diagnostic
ArcherDX has signed on to a new multiyear partnership with DNA sequencing giant Illumina to help broaden the use of its cancer tests.
Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.
Merck will work with Promega to develop the company’s microsatellite instability technology into an official companion diagnostic for Keytruda.
Illumina and Qiagen signed on to a long-term diagnostics partnership—with the latter opting to develop kits for the sequencing giant’s hardware.
The agreement tasks Prometheus with identifying and validating three IBD drug targets in return for up to $420 million in milestones.
Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.